CClinicalTrials.gg
Sign In
CompletedNCT02798016Updated Jan 3, 2018

Treatment of Atrophic Acne Scars With Platelet-Rich Plasma and Skin Needling

An interventional study of Platelet-Rich Plasma and Micro-needling in Atrophic Acne Scars, sponsored by Damascus University. Completed at 1 site in Syrian Arab Republic. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-01-03.

Sponsored by Damascus University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Oct 2015, registered May 2016).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Investigators will collect blood specimens from the participating patients and then blood samples will be centrifuged in order to collect platelet-rich plasma which is going to be injected in the atrophic acne scars. A split-face design is going to used in this randomized controlled trial. In the control side of the face, micro-needling to the skin will occur using a specific tool (Dermapen).

Read the detailed description

Atrophic acne scar is a common problem with a challenging treatment. Platelet-rich plasma (PRP) is an autologous preparation of platelets in concentrated plasma that may be beneficial in the treatment of atrophic acne scars by promoting collagen deposition.

Skin needling is a technique that uses a sterile micro needles to puncture the skin and release growth factors. The combination of skin needling and PRP could enhance the efficacy of both modalities.

02

Conditions studied

  • Atrophic Acne Scars

Browse trials for

03

In context

Atrophy

828 studies on the registry are indexed under Atrophy; 122 are open to participants now.

This study's enrollment of 50 is above the median of 34 across 603 interventional studies indexed under Atrophy.

Browse Atrophy studies →

Lead sponsor

Damascus University is the lead sponsor of 206 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Atrophic acne scars on both sides of the face

Exclusion criteria

Exclusion Criteria:

  • patients with active acne, herpes labialis, or bacterial infection; warts on the face, actinic keratosis, or skin cancer
  • systemic retinoids intake in the previous 6 months,
  • diabetes, pregnancy, history of keloidal scarring; or patients with severe systemic illness or malignancy
  • patients on anticoagulant therapy or aspirin or have a coagulation issue,
  • patients with hemoglobin less than 10g\dl or platelet less than 105 micron\l
  • any previous procedures for acne scar within the last 6 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Platelet-Rich Plasma alone

    The scars will be injected with Platelet-Rich Plasma alone.

    Procedure: Platelet-Rich Plasma

  • Active comparator
    Platelet-Rich Plasma with micro-needling

    The scars will be dealt with using micro-needling as well as injecting Platelet-Rich Plasma

    Procedure: Platelet-Rich Plasma · Procedure: Micro-needling

Interventions

  • ProcedurePlatelet-Rich Plasma

    This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars

  • ProcedureMicro-needling

    Micro-needling will be applied on the acne scars in one side of the face.

06

What researchers measure

Primary outcomes

  1. Change in Scar Appearance

    Time frame: Scar Appearance will be assessed at: T1; one day (wihtin 24 hours) before the application of the intervention(s); and T2: after three months of applying the intervention(s).

Secondary outcomes

  1. Patients' Satisfaction

    The assessment will be based on a questionnaire

    Time frame: This is going to be assessed six months following the application of the intervention and the active comparator

07

Study locations

1 site
  • Department of Dermatology and Venereology
    Damascus, DM20AM18, Syrian Arab Republic
08

References and documents

Publications

  • Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol. 1994 Jul;19(4):303-8. doi: 10.1111/j.1365-2230.1994.tb01200.x. PubMed 7955470 ↗
  • Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J. 1979 Apr 28;1(6171):1109-10. doi: 10.1136/bmj.1.6171.1109. PubMed 156054 ↗
  • Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999 Oct;41(4):577-80. PubMed 10495379 ↗
  • Sunitha Raja V, Munirathnam Naidu E. Platelet-rich fibrin: evolution of a second-generation platelet concentrate. Indian J Dent Res. 2008 Jan-Mar;19(1):42-6. doi: 10.4103/0970-9290.38931. PubMed 18245923 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02798016
Lead sponsor
Damascus University
Responsible party
Sponsor
First posted
Jun 14, 2016
Start date
Oct 2015
Primary completion
Jun 23, 2017
Completion
Oct 20, 2017
Last update
Jan 3, 2018

Study contacts

Faiez Al-Deghlaoui, MD MSc PhD
study director · Associate Professor of Dermatology and Veneology, Medical School, University of Damascus

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Atrophy→

Other studies from this sponsor

Damascus University

Start the discussion